Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityENZY / Enzymotec Ltd. (M4059L101)
Institutional Owners3
Institutional Shares2,874,597
Institutional Value$ 2,586,000 USD

Institutional Stock Ownership and Shareholders()

ENZY / Enzymotec Ltd. Institutional Ownership

Enzymotec Ltd. (NASDAQ:ENZY) has 3 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,874,597 shares. Largest shareholders include Yelin Lapidot Holdings Management Ltd., Janus Capital Management Llc, and BlackRock Institutional Trust Company, N.A..
Enzymotec Ltd. (NASDAQ:ENZY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/enzy"><img src="https://images.fintel.io/us-enzy-so.png" alt="ENZY / Enzymotec Ltd. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR Renaissance Technologies LLC 642,700 0 -100.00 7,616 0 -100.00
2018-05-15 13F-HR Delek Group, Ltd. 2,001,498 0 -100.00 23,684 0 -100.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 46,046 0 -100.00 546 0 -100.00
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 42,200 0 -100.00 500 0 -100.00
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 290,111 290,111 0.00 1,900 2,553 34.37
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 10,623 0 -100.00 126 0 -100.00
2018-05-03 13F-HR SG Americas Securities, LLC 9,800 0 -100.00 116 0 -100.00
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 1,043 0 -100.00 12 0 -100.00
2018-05-15 13F-HR Paloma Partners Management Co 63,623 0 -100.00 754 0 -100.00
2018-05-14 13F-HR Virtu Financial LLC 12,923 0 -100.00 153 0 -100.00
2018-05-11 13F-HR MACQUARIE GROUP LTD 2,200 0 -100.00 26 0 -100.00
2018-05-15 13F-HR BERKLEY W R CORP 275,475 0 -100.00 3,264 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 15,789 5,069 -67.90 111 33 -70.27
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 154,900 0 -100.00 1,836 0 -100.00
2018-05-10 13F-HR Cavalier Investments 22,000 0 -100.00 261 0 -100.00
2018-05-10 13F-HR JP Morgan Chase & Co 6,658 0 -100.00 79 0 -100.00
2018-05-09 13F-HR GABELLI SECURITIES, INC. 191,550 0 -100.00 2,270 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 400 0 -100.00 5 0 -100.00
2018-05-11 13F-HR VAN ECK ASSOCIATES CORP 3,476 0 -100.00 41 0 -100.00
2018-05-15 13F-HR PAULSON & CO. INC. 2,102,990 0 -100.00 24,920 0 -100.00
2018-05-10 13F-HR Spark Investment Management LLC 11,500 0 -100.00 136 0 -100.00
2018-05-15 13F-HR GAM Holding AG 529,620 0 -100.00 6,276 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 187,170 0 -100.00 2,218 0 -100.00
2018-05-09 13F-HR GABELLI FUNDS LLC 576,600 0 -100.00 6,833 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 101,587 0 -100.00 1,203 0 -100.00
2018-05-15 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 108,941 0 -100.00 1,291 0 -100.00
2018-05-14 13F-HR WATER ISLAND CAPITAL LLC 400,000 0 -100.00 4,740 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 2,790 0 -100.00 33 0 -100.00
2018-05-09 13F-HR GAMCO INVESTORS, INC. ET AL 30,450 0 -100.00 361 0 -100.00
2018-05-15 13F-HR MENTA CAPITAL LLC 34,314 0 -100.00 407 0 -100.00
2018-05-15 13F-HR Circle Road Advisors Lp 392,725 0 -100.00 4,654 0 -100.00
2017-02-08 SC 13G/A Yelin Lapidot Holdings Management Ltd. 2,130,237 2,579,417 21.09
2018-05-08 13F-HR Kassirer Asset Management Corp 220,800 0 -100.00 0 0
2018-05-15 13F-HR ETF MANAGERS GROUP, LLC 12,083 0 -100.00 143 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 10,987 0 -100.00 130 0 -100.00
2018-05-15 13F-HR WOLVERINE ASSET MANAGEMENT LLC 11,700 0 -100.00 138 0 -100.00
2018-05-21 13F-HR Navellier & Associates Inc 22,000 0 -100.00 261 0 -100.00
2018-02-14 13F-HR GLG Partners LP 16,096 0 -100.00 184 0 -100.00

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

CUSIP: M4059L101